ALNY – Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.ALNY
$454.38Name : Alnylam Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $59,559,677,952.00
EPSttm : -2.45
Alnylam Pharmaceuticals, Inc.
$454.38
2.82%$13.17Float Short %
2.58
Margin Of Safety %
Put/Call OI Ratio
1.1
EPS Next Q Diff
2.77
EPS Last/This Y
6.1
EPS This/Next Y
5.25
Price
454.41
Target Price
452.08
Analyst Recom
1.69
Performance Q
57.22
Relative Volume
1.02
Beta
0.3
Ticker: ALNY
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-25 | ALNY | 329.01 | 0.94 | 0.77 | 12914 |
| 2025-07-28 | ALNY | 324.99 | 0.94 | 1.33 | 12976 |
| 2025-07-29 | ALNY | 330.81 | 0.97 | 0.05 | 13199 |
| 2025-07-30 | ALNY | 339.77 | 0.93 | 0.43 | 13570 |
| 2025-07-31 | ALNY | 391.17 | 0.89 | 1.00 | 14436 |
| 2025-08-01 | ALNY | 401.59 | 0.97 | 1.01 | 15465 |
| 2025-08-04 | ALNY | 419.58 | 1.01 | 0.87 | 16299 |
| 2025-08-05 | ALNY | 418.91 | 1.04 | 3.90 | 17113 |
| 2025-08-06 | ALNY | 428.14 | 1.08 | 1.77 | 17605 |
| 2025-08-07 | ALNY | 435.18 | 1.13 | 2.86 | 18164 |
| 2025-08-08 | ALNY | 438.94 | 1.16 | 0.95 | 18449 |
| 2025-08-11 | ALNY | 434.9 | 1.15 | 0.43 | 18484 |
| 2025-08-12 | ALNY | 429.6 | 1.17 | 0.45 | 18747 |
| 2025-08-13 | ALNY | 432.77 | 1.16 | 3.26 | 18905 |
| 2025-08-14 | ALNY | 442.54 | 1.17 | 0.54 | 19101 |
| 2025-08-15 | ALNY | 449.19 | 1.16 | 0.36 | 19185 |
| 2025-08-18 | ALNY | 457.8 | 1.11 | 0.72 | 14998 |
| 2025-08-19 | ALNY | 458.33 | 1.09 | 0.38 | 15495 |
| 2025-08-20 | ALNY | 459.98 | 1.08 | 0.88 | 15679 |
| 2025-08-21 | ALNY | 467.59 | 1.08 | 1.88 | 16233 |
| 2025-08-22 | ALNY | 454.31 | 1.10 | 0.80 | 16687 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-25 | ALNY | 328.81 | -77.2 | 276.8 | 1.56 |
| 2025-07-28 | ALNY | 325.10 | -77.2 | 275.8 | 1.56 |
| 2025-07-29 | ALNY | 330.55 | -77.2 | 277.8 | 1.56 |
| 2025-07-30 | ALNY | 339.80 | -77.2 | 278.5 | 1.56 |
| 2025-07-31 | ALNY | 392.24 | -77.2 | 409.9 | 1.56 |
| 2025-08-01 | ALNY | 401.80 | -74.0 | 386.9 | 1.74 |
| 2025-08-04 | ALNY | 419.55 | 377.1 | 407.5 | 4.03 |
| 2025-08-05 | ALNY | 418.91 | 377.1 | 399.4 | 4.03 |
| 2025-08-06 | ALNY | 428.12 | 403.0 | 654.7 | 3.94 |
| 2025-08-07 | ALNY | 435.10 | 403.0 | 652.2 | 3.94 |
| 2025-08-08 | ALNY | 438.93 | 388.3 | 649.0 | 3.90 |
| 2025-08-11 | ALNY | 434.87 | 388.3 | 641.2 | 3.90 |
| 2025-08-12 | ALNY | 429.56 | 384.6 | 639.8 | 3.89 |
| 2025-08-13 | ALNY | 432.52 | 384.6 | 647.8 | 3.89 |
| 2025-08-14 | ALNY | 442.82 | 387.4 | 655.4 | 3.92 |
| 2025-08-15 | ALNY | 449.14 | 387.4 | 651.4 | 3.92 |
| 2025-08-18 | ALNY | 456.87 | 387.4 | 652.8 | 3.92 |
| 2025-08-19 | ALNY | 458.28 | 387.4 | 646.5 | 3.92 |
| 2025-08-20 | ALNY | 458.46 | 387.4 | 645.4 | 3.92 |
| 2025-08-21 | ALNY | 467.59 | 387.4 | 653.9 | 3.92 |
| 2025-08-22 | ALNY | 454.41 | 387.4 | 633.2 | 3.92 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-25 | ALNY | -2.66 | 1.64 | 2.71 |
| 2025-07-28 | ALNY | -2.66 | 1.47 | 2.71 |
| 2025-07-29 | ALNY | -2.66 | 1.47 | 2.71 |
| 2025-07-30 | ALNY | -1.78 | 1.47 | 2.71 |
| 2025-07-31 | ALNY | -1.78 | 1.47 | 2.71 |
| 2025-08-01 | ALNY | -1.78 | 1.47 | 2.71 |
| 2025-08-04 | ALNY | -1.77 | 1.03 | 2.70 |
| 2025-08-05 | ALNY | -1.77 | 1.03 | 2.70 |
| 2025-08-06 | ALNY | -1.77 | 1.03 | 2.70 |
| 2025-08-07 | ALNY | -1.77 | 1.03 | 2.70 |
| 2025-08-08 | ALNY | -1.77 | 1.03 | 2.70 |
| 2025-08-11 | ALNY | -1.77 | 1.04 | 2.70 |
| 2025-08-12 | ALNY | -1.77 | 1.04 | 2.58 |
| 2025-08-13 | ALNY | -1.77 | 1.04 | 2.58 |
| 2025-08-14 | ALNY | -1.77 | 1.04 | 2.58 |
| 2025-08-15 | ALNY | -2.30 | 1.04 | 2.58 |
| 2025-08-18 | ALNY | -2.30 | 0.58 | 2.58 |
| 2025-08-19 | ALNY | -2.61 | 0.58 | 2.58 |
| 2025-08-20 | ALNY | -2.69 | 0.58 | 2.58 |
| 2025-08-21 | ALNY | -2.69 | 0.58 | 2.58 |
| 2025-08-22 | ALNY | -2.69 | 0.58 | 2.58 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.52
Avg. EPS Est. Current Quarter
1.44
Avg. EPS Est. Next Quarter
2.25
Insider Transactions
-2.69
Institutional Transactions
0.58
Beta
0.3
Average Sales Estimate Current Quarter
942
Average Sales Estimate Next Quarter
1197
Fair Value
Quality Score
42
Growth Score
49
Sentiment Score
93
Actual DrawDown %
2.8
Max Drawdown 5-Year %
-42.5
Target Price
452.08
P/E
Forward P/E
71.84
PEG
P/S
24.19
P/B
237.49
P/Free Cash Flow
EPS
-2.47
Average EPS Est. Cur. Y
3.92
EPS Next Y. (Est.)
9.17
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
-12.96
Relative Volume
1.02
Return on Equity vs Sector %
-152
Return on Equity vs Industry %
-139.1
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
2.68
EBIT Estimation
633.2
Alnylam Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 2230
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
stock quote shares ALNY – Alnylam Pharmaceuticals, Inc. Stock Price stock today
news today ALNY – Alnylam Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALNY – Alnylam Pharmaceuticals, Inc. yahoo finance google finance
stock history ALNY – Alnylam Pharmaceuticals, Inc. invest stock market
stock prices ALNY premarket after hours
ticker ALNY fair value insiders trading